PTC Therapeutics, Inc. Marketable Securities (Current)
PTC Therapeutics, Inc. (PTCT) had Marketable Securities (Current) of $1.18 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-07-30
- 2026-06-30: Marketable Securities, Current $1.18B.
- 2026-03-31: Marketable Securities, Current $1.06B.
- 2025-12-31: Marketable Securities, Current $960.72M.
- 2025-09-30: Marketable Securities, Current $1.02B.
| Period end | Marketable Securities, Current | Marketable Securities, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.18B 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $1.06B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $960.72M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $1.02B 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $971.76M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $546.95M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $359.99M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $487.36M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $438.51M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $336.46M 10-Q · filed 2024-04-25 | |
| 2023-12-31 | $282.74M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $129.65M 10-Q · filed 2023-10-26 | |
| 2023-06-30 | $129.55M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $118.81M 10-Q · filed 2023-04-27 | |
| 2022-12-31 | $130.87M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $184.01M 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $347.39M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $443.62M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $583.66M 10-K · filed 2023-02-21 | |
| 2021-09-30 | $678.13M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $769.73M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $841.77M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $894.84M 10-K · filed 2022-02-22 | |
| 2020-09-30 | $707.05M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $340.43M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $472.57M 10-Q · filed 2020-04-30 | |
| 2019-12-31 | $398.54M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $185.07M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $227.45M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $206.02M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $58.09M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $42.49M 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $72.32M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $80.59M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $79.45M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $27.47M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $48.06M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $148.47M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $173.34M 10-K · filed 2018-03-06 | |
| 2016-09-30 | $198.05M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $237.24M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $258.55M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $280.90M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $230.81M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $226.00M 10-Q · filed 2015-07-31 | |
| 2015-03-31 | $243.64M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $265.49M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $156.52M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $205.69M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $130.73M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $127.05M 10-K · filed 2015-03-02 | $127.05M 10-K · filed 2014-03-06 |
| 2013-09-30 | $133.18M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $11.58M 10-Q · filed 2013-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |